DVA DaVita Inc.

DVA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving DaVita Inc. and a Lead Plaintiff Deadline of April 3, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Colorado on behalf of investors who purchased DaVita Inc. (NYSE:DVA) securities between August 5, 2015 and October 21, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/davita-inc. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) DaVita and its senior executives purposefully steered patients into needless insurance plans to maximize profits; (2) DaVita was using American Kidney Fund to facilitate these inappropriate practices; (3) therefore DaVita’s revenues and profits were illegally acquired; (4) as a result, DaVita lacked effective internal controls over financial reporting.

On January 6, 2017, the Wall Street Journal published an article revealing that DaVita had received subpoenas from federal prosecutors seeking “the production of information related to charitable premium assistance” in connection with DaVita’s ties to the American Kidney Fund, a charity that helps patients pay for kidney dialysis.

If you suffered a loss in DaVita you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/davita-inc.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
13/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DaVita Inc.

Davita Inc: 1 director

A director at Davita Inc sold 2,351 shares at 150.000USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Moody's Ratings assigns Ba3 rating to DaVita's proposed senior unsecur...

Moody's Ratings (Moody's) assigned a Ba3 rating to DaVita Inc.'s ("DaVita" or "the company") proposed senior unsecured notes. There is no change to the company's existing ratings, including the Ba2 corporate family rating (CFR), Ba2-PD probability of default rating (PDR), Ba1 senior secured bank cre...

DaVita Inc.: Update to credit analysis

Our credit view of this issuer reflects its strong free cash flow and its considerable scale and strong US market position, against its track record of debt-funded share repurchases.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of DaVita Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 15 January 2025 in which we reassessed the appropriateness of the ratings in the context of the...

Moody's Ratings assigns Ba3 rating to DaVita's proposed senior unsecur...

Moody's Ratings (Moody's) assigned a Ba3 rating to DaVita Inc.'s ("DaVita" or "the company") proposed offering of $1 billion senior unsecured notes. There is no change to the company's existing ratings, including the Ba2 corporate family rating (CFR), Ba2-PD probability of default rating (PDR), Ba1 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch